论文部分内容阅读
急性冠脉综合征(ACS)是临床上常见的心血管疾病,双联抗血小板治疗是ACS和经皮冠状动脉介入术后患者标准的抗血小板治疗方案,可减少心血管事件的发生,包括心血管死亡、支架内血栓、心肌梗死和脑血管意外等。替格瑞洛是一种新型P2Y12抑制剂,相比氯吡格雷起效快,抑制血小板的作用强且均一,可改善ACS患者预后;特别是对于血栓负荷重的ACS患者、冠状动脉多支复杂病变及对氯吡格雷低反应患者,可更为
Acute coronary syndrome (ACS) is a clinically common cardiovascular disease and dual antiplatelet therapy is the standard antiplatelet regimen for patients after ACS and percutaneous coronary intervention to reduce the incidence of cardiovascular events, including heart Vascular death, stent thrombosis, myocardial infarction and cerebrovascular accident. Ticagrelor is a novel P2Y12 inhibitor with rapid onset of action over clopidogrel and strong and uniform inhibition of platelets, which can improve the prognosis of patients with ACS. In particular, coronary artery disease is more complicated in ACS patients with thrombus burden Lesions and patients with low response to clopidogrel may be more